CL2007001919A1 - Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos. - Google Patents

Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos.

Info

Publication number
CL2007001919A1
CL2007001919A1 CL200701919A CL2007001919A CL2007001919A1 CL 2007001919 A1 CL2007001919 A1 CL 2007001919A1 CL 200701919 A CL200701919 A CL 200701919A CL 2007001919 A CL2007001919 A CL 2007001919A CL 2007001919 A1 CL2007001919 A1 CL 2007001919A1
Authority
CL
Chile
Prior art keywords
compounds
metilen
espirox
metil
onas
Prior art date
Application number
CL200701919A
Other languages
English (en)
Inventor
Bohlmann Jaochim Kuhnke J Rolf
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38626491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001919(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CL2007001919A1 publication Critical patent/CL2007001919A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
CL200701919A 2006-06-29 2007-06-29 Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos. CL2007001919A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006030416A DE102006030416A1 (de) 2006-06-29 2006-06-29 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
CL2007001919A1 true CL2007001919A1 (es) 2008-05-16

Family

ID=38626491

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200701919A CL2007001919A1 (es) 2006-06-29 2007-06-29 Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos.

Country Status (41)

Country Link
US (1) US7846917B2 (es)
EP (1) EP2038294B1 (es)
JP (1) JP5326085B2 (es)
KR (1) KR101440640B1 (es)
CN (1) CN101511857B (es)
AR (1) AR061736A1 (es)
AT (1) ATE490967T1 (es)
AU (1) AU2007263944B2 (es)
BR (1) BRPI0713934A2 (es)
CA (1) CA2656443C (es)
CL (1) CL2007001919A1 (es)
CO (1) CO6150134A2 (es)
CR (1) CR10548A (es)
CY (1) CY1111658T1 (es)
DE (2) DE102006030416A1 (es)
DK (1) DK2038294T3 (es)
DO (1) DOP2008000089A (es)
EC (1) ECSP089014A (es)
ES (1) ES2357698T3 (es)
GT (1) GT200800307A (es)
HK (1) HK1133659A1 (es)
HN (1) HN2008001934A (es)
HR (1) HRP20110161T1 (es)
IL (1) IL195935A0 (es)
MA (1) MA30596B1 (es)
MX (1) MX2009000082A (es)
MY (1) MY155015A (es)
NO (1) NO20090459L (es)
NZ (1) NZ573951A (es)
PE (1) PE20080995A1 (es)
PL (1) PL2038294T3 (es)
PT (1) PT2038294E (es)
RS (1) RS51722B (es)
RU (1) RU2440365C2 (es)
SI (1) SI2038294T1 (es)
TN (1) TNSN08518A1 (es)
TW (1) TWI413645B (es)
UA (1) UA94952C2 (es)
UY (1) UY30451A1 (es)
WO (1) WO2008000521A1 (es)
ZA (1) ZA200900673B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
WO2013160200A1 (de) * 2012-04-23 2013-10-31 Bayer Pharma Aktiengesellschaft ANWENDUNG VON 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONEN BEI DER THERAPIE DER MENORRHAGIA, SOWIE 18-METHYL-15ß,16ß-METHYLEN-19-NOR-20-SPIROX-4-EN-3-ONE ENTHALTENDE INTRAUTERINE SYSTEME FÜR DIE THERAPIE UTERINEN BLUTUNGSSTÖRUNGEN
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
WO2015055789A1 (en) * 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
US20160262923A1 (en) * 2013-10-18 2016-09-15 Bayer Oy Intrauterine delivery system
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CN109575094B (zh) * 2019-01-17 2021-01-26 浙江仙琚制药股份有限公司 替勃龙中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798213A (en) * 1971-01-25 1974-03-19 Merck & Co Inc 7 alpha-methyl-20-spiroxane-3-ones and process
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3111950A1 (de) 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP1148061B1 (en) 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter

Also Published As

Publication number Publication date
UY30451A1 (es) 2008-01-31
ATE490967T1 (de) 2010-12-15
HN2008001934A (es) 2012-01-17
DOP2008000089A (es) 2009-02-15
RU2440365C2 (ru) 2012-01-20
DE502007005902D1 (de) 2011-01-20
PL2038294T3 (pl) 2011-05-31
ECSP089014A (es) 2009-01-30
TNSN08518A1 (en) 2010-04-14
BRPI0713934A2 (pt) 2012-12-04
UA94952C2 (uk) 2011-06-25
JP5326085B2 (ja) 2013-10-30
HK1133659A1 (es) 2010-04-01
TW200811193A (en) 2008-03-01
DE102006030416A1 (de) 2008-01-03
CA2656443A1 (en) 2008-01-03
PT2038294E (pt) 2011-03-14
RS51722B (en) 2011-10-31
CN101511857A (zh) 2009-08-19
WO2008000521A1 (de) 2008-01-03
CN101511857B (zh) 2012-10-31
IL195935A0 (en) 2009-09-01
CY1111658T1 (el) 2015-10-07
US20080153787A1 (en) 2008-06-26
NZ573951A (en) 2011-06-30
KR20090021294A (ko) 2009-03-02
JP2009541405A (ja) 2009-11-26
CO6150134A2 (es) 2010-04-20
EP2038294B1 (de) 2010-12-08
HRP20110161T1 (hr) 2011-04-30
AR061736A1 (es) 2008-09-17
GT200800307A (es) 2009-11-03
US7846917B2 (en) 2010-12-07
TWI413645B (zh) 2013-11-01
CR10548A (es) 2009-01-27
MA30596B1 (fr) 2009-07-01
ZA200900673B (en) 2010-04-28
ES2357698T3 (es) 2011-04-28
AU2007263944A1 (en) 2008-01-03
MY155015A (en) 2015-08-28
CA2656443C (en) 2014-10-07
EP2038294A1 (de) 2009-03-25
NO20090459L (no) 2009-03-10
KR101440640B1 (ko) 2014-09-22
AU2007263944B2 (en) 2013-07-18
PE20080995A1 (es) 2008-10-03
DK2038294T3 (da) 2011-03-28
SI2038294T1 (sl) 2011-04-29
MX2009000082A (es) 2009-01-23
RU2009102772A (ru) 2010-08-10

Similar Documents

Publication Publication Date Title
CL2007001919A1 (es) Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos.
LTC2187879I2 (lt) Farmacinė kompozicija, apimanti gliukopiranozil-pakeistojo benzeno darinį
NL2000581A1 (nl) Aangecondenseerde fenylamidoheterocyclische verbindingen.
BRPI0716094A2 (pt) composiÇço de resina.
BRPI0815717A2 (pt) Compostos de imidazopirazina.
BRPI0719398A2 (pt) Composição farmacêutica.
DK2041123T3 (da) Kondenserede cykliske forbindelser.
BRPI0810646A2 (pt) " compostos farmacêuticos ".
EP2031966A4 (en) ODOR-FREE SOLVENT WITH LOW VOLATILE FOR AGRICULTURAL CHEMICALS
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
BRPI0814745A2 (pt) Composição de produto.
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
CL2007002424A1 (es) Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer.
BRPI0812354A2 (pt) Composição farmacêutica não-aquosa.
FR2909442B1 (fr) Telemetre.
CL2007003470A1 (es) Compuestos derivados de urea; composicion farmaceutica que comprende a dichos compuestos; y su uso como antibacterianos.
CR10353A (es) Nuevos compuestos.
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
BRPI0716046A2 (pt) composiÇÕes de nanopartÍcula.
FR2930460B1 (fr) Distributeur de fragrance.
BRPI0816682A2 (pt) Correção de deslocamento para misturadores passivos.
FR2899996B1 (fr) Disjoncteur.
CL2008001305A1 (es) Compuestos derivados de azetidina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar endometriosis y/o miomas uterinos.
CL2007002812A1 (es) Compuestos derivados de quinolina; composicion farmaceutica, utiles para inhibir el vih.